Kernal Biologics is pioneering advancements in mRNA therapeutics through its innovative mRNA 2.0 platform, which focuses on selectively translating mRNAs into therapeutic proteins within targeted cells. This technology is designed to enhance the efficacy and tolerability of treatments by ensuring that mRNAs are delivered precisely to the right tissues and cell types, particularly in challenging environments like tumors. The company utilizes antibody-decorated lipid nanoparticles (LNPs) to achieve high delivery efficiency, with reported rates exceeding 90%. This targeted approach minimizes off-target effects, making it a significant improvement over traditional mRNA design methods.

In addition to its selective translation capabilities, Kernal Biologics is addressing the challenges of scaling up mRNA-LNP therapeutics through novel manufacturing solutions. The company is focused on optimizing the production processes for its immunotherapeutic candidates, such as KR-335, which has shown a remarkable therapeutic index in preclinical models. By leveraging machine learning to identify RNA sequence motifs that enhance translation based on cell type, Kernal Bio is not only advancing the field of mRNA therapeutics but also ensuring that these therapies can be developed and manufactured efficiently while maintaining high quality and safety standards.

United States

Kernal creates mRNA therapies to cure severe diseases including cancer. Our mRNA therapies instruct specific cells on how to make their own drugs. With roots at MIT, Harvard and Big Pharma, our team previously built a successful Biotech company and has deep expertise in mRNA space.

Kernal Biologics

Company Details